CHMP Nod Little Consolation As Amgen's Imlygic Becomes Melanoma Also-Ran
This article was originally published in Scrip
Executive Summary
Amgen's oncolytic virus therapy Imlygic (talimogene laherparepvec) has been given a positive opinion in advanced melanoma by Europe's top scientific advisory panel, but significant changes in the competitive landscape mean the drug is unlikely to garner high sales.